NASDAQ · PYXS
Pyxis Oncology, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PYXS: Nov 2, 2026
Pyxis Oncology, Inc. Common Stock is estimated to report earnings on 11/02/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.27. The reported EPS for the same quarter last year was $-0.35.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.27 | $-0.25 | $-0.31 | 4 |
| Dec 2026 | $-0.25 | $-0.20 | $-0.31 | 4 |
| Mar 2027 | $-0.25 | $-0.18 | $-0.29 | 3 |
| Jun 2027 | $-0.25 | $-0.18 | $-0.30 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · BNK Invest · NASDAQ.com- RTTNews · Sep 30, 6:09 AM EDTPyxis Prices $110 Mln Offering, With Potential Proceeds Of $282 Mln To Advance Lead Cancer Drug(RTTNews) – On Wednesday Pyxis Oncology (PYXS), a clinical-stage biopharmaceutical, announced the pricing of its previously announced public offering, expected to generate approximately $110 million in gross proceeds.
- Fintel · Sep 14, 10:18 PM EDTPyxis Oncology Consensus Price Target Increased by 16.92% to $8.61The average one-year price target for Pyxis Oncology (NASDAQGS:PYXS) has been revised to $8.61 / share. This is an increase of 16.92% from the prior estimate of $7.37 dated August 25, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitut
- RTTNews · Sep 11, 12:06 PM EDTWeekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials(RTTNews) – Biotech and healthcare saw regulatory approvals, strategic partnerships, M&A activity, and a steady stream of clinical trial updates driving investor attention.
- RTTNews · Sep 9, 8:05 AM EDTPyxis Oncology Reports Positive MICVO Phase 1 Data In 2L+ Head And Neck Cancer(RTTNews) – Pyxis Oncology, Inc. (PYXS) announced positive updated data from its ongoing Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in patients with second-line and beyond (2L+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
- RTTNews · Sep 8, 11:31 PM EDTBiotech Movers: Modular Medical Jumps, InnovAge Revenue Up 16%, Pyxis Data On Deck, Dogwood In Focus(RTTNews) – With heightened trade tensions between the U.S. and Canada and rising oil prices weighing on investor sentiment, U.S. stocks came under pressure on Tuesday. Against this backdrop, the SPDR S&P Biotech ETF (XBI), a broad benchmark for the U.S. biotechnology sector, dec
- RTTNews · Sep 8, 8:06 AM EDTPyxis Oncology Confirms Thomas Civikas As CEO And Chairman(RTTNews) – Pyxis Oncology, Inc. (PYXS), a clinical-stage company, announced Tuesday that its Board of Directors has appointed Thomas Civik as Chief Executive Officer and Chairman of the Board, effective as of September 4, 2026.
- RTTNews · Sep 4, 2:36 PM EDT5 Biotech And Medical Device Stocks In Focus: Pro-Dex, Modular Medical, ENvue Medical & More(RTTNews) – Several biotech and medical device stocks were in focus Friday, including Pro-Dex following strong fiscal 2026 results; Modular Medical after FDA clearance for Pivot patch pump software enhancements; and ENvue Medical following its selection for the Vizient Innovative
- RTTNews · Sep 4, 10:56 AM EDTPyxis Oncology Eyes Key MICVO Catalysts With Three September Conference Appearances(RTTNews) – Pyxis Oncology, Inc. (PYXS), a clinical-stage biopharmaceutical company developing therapies for difficult-to-treat cancers, recently announced that Interim Chief Executive Officer and Director Tom Civik will participate in fireside chats at three upcoming healthcare
- BNK Invest · Jul 7, 12:54 PM EDTTuesday Sector Leaders: Drugs, Gas UtilitiesIn trading on Tuesday, drugs shares were relative leaders, up on the day by about 2%. Leading the group were shares of Crinetics Pharmaceuticals, up about 98.8% and shares of Pyxis Oncology up about 18.7% on the day. Also showing relative strength are gas utilities shares, up
- NASDAQ.com · Jun 30, 8:28 AM EDTPre-Market Most Active for Jun 30, 2026 : VWAV, CAST, RDW, TQQQ, NOK, IBIT, PYXS, TSLL, KRG, JOBY, EPD, QXOThe NASDAQ 100 Pre-Market Indicator is up 10.98 to 29,785.73. The total Pre-Market volume is currently 93,304,552 shares traded.The following are the most active stocks for the pre-market session: VisionWave Holdings, Inc. (VWAV) is +0.5 at $5.12, with 8,563,784 shares traded.Fr
- Fintel · May 5, 11:52 AM EDTWedbush Initiates Coverage of Pyxis Oncology (PYXS) with Outperform RecommendationFintel reports that on May 5, 2026, Wedbush initiated coverage of Pyxis Oncology (NasdaqGS:PYXS) with a Outperform recommendation. Analyst Price Forecast Suggests 298.44% Upside
- RTTNews · Mar 23, 11:21 AM EDTPyxis' FY25 Net Loss Expands; Expects To Report Updated MICVO Phase 1 Monotherapy Data In Mid 2026(RTTNews) – Pyxis Oncology, Inc. (PYXS), a clinical-stage company, reported financial results for the full year 2025, reflecting an expanded net loss and provided near-term milestones for its lead investigational candidate, MICVO, for the treatment of solid tumours.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Pyxis Oncology, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.